Trials / Terminated
TerminatedNCT05859464
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumor Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Zai Lab (Hong Kong), Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZL-1218 | ZL-1218 dose escalation |
| DRUG | Pembrolizumab | Combination treatment with ZL-1218 |
Timeline
- Start date
- 2023-07-24
- Primary completion
- 2025-08-28
- Completion
- 2025-08-28
- First posted
- 2023-05-16
- Last updated
- 2025-10-20
Locations
15 sites across 3 countries: United States, China, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05859464. Inclusion in this directory is not an endorsement.